In a stunner, Merck lands positive PhIII for its CETP outcast anacetrapib
Long after many analysts had given Merck’s CETP heart drug anacetrapib up for dead following a slate of expensive burials for the first three drugs in the class, the pharma giant managed to shock the industry this morning with news that their drug came through a 30,000-patient study with convincing data of its effectiveness.
In a brief statement on the topline results, the pharma giant noted that its drug significantly reduced the risk of a coronary event – a composite of coronary death, myocardial infarction, and coronary revascularization – among high-risk patients who had already been through LDL-lowering therapy effectively.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.